2.6 Medication Therapy Management & Collaborative Goals of Therapy

2.6 Medication Therapy Management & Collaborative Goals of Therapy

Domain 2 of the CPJE rewards pharmacists who can run a care process, not only recite guidelines. Outline items 2A1 (develop a therapeutic regimen / perform MTM), 2A4 (collaborate on goals), 2A5 (assess health-status changes), and 2A6 (monitoring and therapeutic management) describe how California pharmacists move from a filled prescription to accountable medication management.

MTM as a Structured Service (Not Informal Advice)

Medication Therapy Management is a systematic service model. In Medicare Part D and many commercial programs, core elements include:

1. Interventions for identified medication-related problems during and between reviews.
2. Comprehensive Medication Review (CMR) — interactive, person-to-person (or telehealth-equivalent) review of all medications, usually at least annually for eligible beneficiaries.
3. Personal Medication List (PML) and Medication Action Plan (MAP) provided to the patient.
4. Targeted Medication Reviews (TMRs) — focused follow-ups (often quarterly in Part D models) addressing specific problems (adherence gaps, unsafe combinations, missing guideline-directed therapy).
5. Documentation and prescriber communication of findings and recommendations.

For CPJE, memorize the structure: CMR → problems list → prioritized recommendations → patient action plan → follow-up monitoring. A five-minute “how to take this antibiotic” consult is counseling (Domain 2B); MTM is longitudinal problem-solving across the full regimen.

Building the CMR encounter

Common medication-related problems to classify: unnecessary drug therapy, needs additional therapy, ineffective/wrong drug, dose too low/high, adverse drug reaction, adherence barriers, and cost barriers (linked to formulary/affordability skills).

Collaborative Goals of Therapy (2A4)

Goals that matter are shared, measurable, and time-bound. Collaboration means the pharmacist does not invent endpoints in isolation.

Examples of well-formed collaborative goals:

• “Reduce seated home BP to <130/80 mm Hg within 8 weeks while avoiding symptomatic hypotension.”
• “Achieve PDC (proportion of days covered) ≥80% for high-intensity statin by next CMR.”
• “Eliminate duplicate anticholinergic burden within 30 days after primary care agreement.”

Poor goals sound like “optimize heart meds” with no metric, owner, or timeframe.

Who is on the care team?

Depending on setting: patient/caregiver, primary care clinician, specialists, nurses, case managers, and—when privileges exist—the Advanced Practice Pharmacist or CDTM pharmacist adjusting therapy under protocol. California collaborative practice tools include:

• CDTM / protocol management under B&P § 4052.1 (and related collaborative frameworks) for initiating/adjusting therapy and ordering monitoring tests per written agreement.
• APh authority under B&P § 4052.6 to assess patients and manage drug therapy within the APh designation.
• Independent furnishing protocols (contraception, NRT, naloxone, PrEP/PEP, immunizations) as bounded regimen decisions that still require goal-aligned counseling and documentation.

When recommending regimen changes outside independent authority, transmit a clear recommendation (drug, dose, rationale, monitoring) to the prescriber and document acceptance, modification, or rejection.

Assessing Changes in Health Status (2A5)

Therapy that was appropriate last quarter may be dangerous today. Triggers for reassessment include:

• New diagnosis (heart failure, CKD, pregnancy, cancer).
• Acute care transitions (hospital discharge with incomplete reconciliation).
• Lab shifts (rising creatinine on ACE inhibitor/ARB/diuretic; INR out of range; A1C rise).
• Clinical events (fall, major bleed, severe hypoglycemia, angioedema).
• Social changes (loss of insurance, new caregiver, cognitive decline).

Process expectation: update the problem list, re-prioritize goals, and decide whether to continue, adjust, hold, or deprescribe—then communicate. Ignoring a status change while refilling old doses is a process failure even if each individual prescription is “technically valid.”

Transition-of-care linkage

Although medication reconciliation is its own outline item (2A13), MTM after discharge often starts with reconciliation findings: stopped inpatient meds restarted incorrectly, therapeutic duplications, or missing prophylaxis. Treat discharge as a mandatory health-status change review.

Monitoring and Therapeutic Management Plans (2A6)

A monitoring plan answers four questions in writing:

1. What will be monitored (symptom, vital, lab, adherence metric, drug level)?
2. When / how often?
3. Who obtains and interprets the result (patient home BP log, pharmacy POC glucose under B&P § 4052.4, APh/CDTM-ordered serum creatinine, clinic nurse)?
4. What action follows abnormal results (dose hold parameters, referral thresholds, protocol titration steps)?

Example — ACE inhibitor start in a collaborative hypertension protocol:

• Check serum creatinine and potassium within 1–2 weeks after initiation or dose increase.
• Hold and contact clinician if K+ exceeds protocol limit or creatinine rises beyond agreed percent change.
• Review home BP log at 2 and 4 weeks toward the shared BP goal.
• Document all values and actions in the shared record or pharmacy MTM platform.

Monitoring without an action threshold is observation theater; action without monitoring is guessing.

California Practice Standards Angle

CPJE items here often test whether you:

• Distinguish counseling from MTM/CMR documentation artifacts (PML/MAP).
• Escalate within legal scope (protocol vs. recommendation).
• Close communication loops with prescribers after interventions.
• Reassess after status changes rather than autopilot refill.
• Tie monitoring to authority to order/interpret tests when practicing under CDTM/APh rules.

You are not expected to memorize every disease guideline on MTM items; you are expected to sequence Collect–Assess–Plan–Implement–Follow-up, write goals a care team can recognize, and know which California authorities allow you to adjust therapy versus only advise.

Putting It Together: Mini Case Pattern

A patient with Type 2 diabetes, new eGFR 42 mL/min, and PDC 55% on metformin and a sulfonylurea presents for CMR. Collaborative goals might include safer glycemic therapy for CKD, adherence ≥80%, and avoidance of hypoglycemia. Assessment of the health-status change (CKD progression) drives metformin dose review and sulfonylurea risk reassessment. The monitoring plan specifies CMP timing, hypoglycemia symptom teaching, and follow-up TMR in 4–6 weeks. Recommendations go to the primary care clinician unless an APh/CDTM protocol already authorizes the adjustment. That narrative—not a lone drug monograph fact—is the CPJE clinical-practice standard.